ABCC5 and in situ carcinoma: MDR1 and MDR3 were previously shown to be involved in the acquisition of resistance to paclitaxel (PTX) and doxorubicin (DOX), respectively, while MRP1, MRP2, and MRP5 play a role in the acquisition of resistance to DOX and/or cisplatin (CIS) [26].